Merck Experimental Therapy Extends Survival in Advanced Endometrial Cancer Trial
Late-stage trial data presented at the ESMO medical congress showed Merck’s experimental targeted drug helped women with advanced endometrial cancer live longer and kept their disease in check versus standard treatment.